These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27382096)

  • 1. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.
    Stefoni V; Argnani L; Carella M; Casadei B; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Coppola PE; Zinzani PL
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1043-1047. PubMed ID: 35239000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
    Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
    Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Zanni M; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Ricci F; Carlo-Stella C
    Blood Adv; 2020 Jan; 4(1):136-140. PubMed ID: 31935284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
    Arai S; Letsinger R; Wong RM; Johnston LJ; Laport GG; Lowsky R; Miklos DB; Shizuru JA; Weng WK; Lavori PW; Blume KG; Negrin RS; Horning SJ
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1145-54. PubMed ID: 20197102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
    Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
    Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
    Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
    J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
    Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
    Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
    Cole PD; Schwartz CL; Drachtman RA; de Alarcon PA; Chen L; Trippett TM
    J Clin Oncol; 2009 Mar; 27(9):1456-61. PubMed ID: 19224841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM; Blum KA
    Cancer; 2020 Mar; 126(6):1235-1242. PubMed ID: 31821549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
    Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
    Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
    Kim DY; Chung JS; Jo JC; Cho SH; Shin HJ
    Ann Hematol; 2020 Apr; 99(4):819-828. PubMed ID: 32025840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
    Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
    Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
    Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.